The success of immunotherapy approaches, such as immune checkpoint blockade and
cellular immunotherapy with genetically modified lymphocytes, has firmly embedded the …

Tertiary lymphoid structures (TLS) are clusters of immune cells that resemble and function
similarly to secondary lymphoid organs (SLOs). While TLS is generally associated with an …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. It is
characterized by a complex and immunosuppressive tumor microenvironment (TME), which …

In recent years, two-dimensional (2D) layer materials have shown great potential in the field
of cancer diagnosis and treatment due to their unique structural, electronic, and chemical …

Tumor molecular data sets are becoming increasingly complex, making it nearly impossible
for humans alone to effectively analyze them. Here, we demonstrate the power of using …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor response to all
therapeutic modalities and dismal prognosis. The presence of tertiary lymphoid structures …

Tumor-associated tertiary lymphoid structures (TLS) have been associated with favorable
clinical outcomes and response to immune checkpoint inhibitors in many cancer types …

Immunotherapy shows substantial advancement in cancer and is becoming widely used in
clinical practice. A variety of biomarkers have been proposed to predict the efficacy of …

Tertiary lymphoid structures (TLS) represent the ectopic aggregations of immune cells
arising during chronic inflammation or tumor progression. In cancer, TLS are often …

Donor lymphocyte infusion (DLI) is an established therapy for relapsed acute myeloid
leukemia (AML) after hematopoietic stem cell transplant (HSCT), but response rates are …